CeriBell, Inc. (CBLL) 股票分析

公司概述

CerriBell, Inc. operates within the United States as a specialized medical technology firm focused on the acute care sector, where it develops the Ceribell System, a point-of-care EEG platform designed to address critical unmet patient needs alongside disposable flexible headbands. The company functions within the Healthcare sector and specifically the Medical Devices industry, positioning itself to serve institutions requiring advanced diagnostic capabilities for neurological monitoring. With a market capitalization of $699.00 million, an annual revenue of $89.06 million, and a workforce of 327 employees, CeriBell, Inc. maintains a mid-market profile typical of specialized biotech or medtech firms. These valuation and revenue figures indicate that the company possesses significant capital resources relative to its sales volume, suggesting a firm that commands substantial market attention despite not yet generating positive net income.

财务健康

The company reported a trailing twelve-month revenue of $89.06 million, yet recorded a net income of $-53,412,000 and an EBITDA of $-57,061,000, revealing a substantial gap between top-line growth and bottom-line profitability indicative of high operating costs or significant investment in R&D and commercialization. This negative free cash flow of $-23,596,500 implies that the company is currently burning cash, which limits immediate financial flexibility but may be strategic for long-term product development. The gross margin stands at 87.9%, demonstrating strong pricing power or low cost of goods sold, whereas the operating margin of -58.9% and profit margin of -60.0% highlight the heavy overhead burdens or loss-making operations typical of early-stage growth companies. On the balance sheet, CeriBell, Inc. holds $159.26 million in cash against $22.28 million in debt, resulting in a debt-to-equity ratio of 14.34, which presents a leveraged profile where cash reserves significantly outweigh obligations. The current ratio of 9.73 indicates exceptional short-term liquidity, as the company possesses nearly ten times the current assets necessary to cover its current liabilities. Furthermore, the return on equity of -30.8% and return on assets of -17.3% reveal that management has yet to deploy capital effectively to generate positive returns for shareholders or asset holders.

估值评估

The valuation metrics present a complex picture, with a trailing P/E ratio marked as N/A due to losses, while the forward P/E stands at -18.47, reflecting the expectation that earnings may remain negative in the near term. The price-to-book ratio is 4.48, indicating that the market values the company at a significant premium over its book value, likely betting on future intellectual property or growth potential rather than current asset liquidity. Alternative metrics such as a price-to-sales ratio of 7.85 and an EV/EBITDA of -9.85 suggest that investors are pricing the stock based on revenue generation rather than profitability. The stock traded within a 52-week range between $10.01 and $24.33; without the specific current price provided in the source facts, the precise percentage deviation from these highs or lows cannot be calculated, though the wide range suggests significant price volatility. The beta value is listed as N/A, which prevents a direct comparison of price volatility relative to the broader market, though the wide trading range of over $14 implies high intrinsic volatility independent of the standard beta metric.

Growth & Income

CerriBell, Inc. achieved a revenue growth rate of 33.7% year-over-year, whereas earnings growth is N/A due to the company's continued losses, implying that top-line expansion is outpacing profitability as the firm scales its operations. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, confirming that all earnings are retained and reinvested into business growth rather than distributed to shareholders. This reinvestment strategy is consistent with the company's cash burn rate and its focus on expanding the Ceribell System market share. The overall growth and income profile is characterized by rapid revenue expansion funded by internal cash reserves rather than external financing or dividend payouts, prioritizing capital appreciation over current income distribution.